Prologis initiated more than $900 million of development starts during the second quarter, according to its earnings report.

After a strong performance in the second quarter, the regional bank's CEO, Bryan Jordan, talked about the resilience of borrowers in the current economic climate.

Early trading on Wall Street was quietly mixed as markets shift their attention toward a deluge of corporate earnings reports ...

The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.